Latest News

Dr Reddy’s has got 13 observations from USFDA for Duwada facility

Dr Reddy’s Laboratories has got 13 observations from the US health regulator for its formulation manufacturing facility at Duwada, Vishakhapatnam.

Dr Redd’s Laboratories has said in a BSE filing that “The audit of company’s formulation manufacturing facility at Duwada, Vishakhapatnam, by the US FDA, has been completed on March 8, 2017. The company have been issued a Form 483 with 13 observations, which the company is addressing.”

However, the company did not specify the observations.

Read EquityPandit’s Technical Analysis on Nifty Pharma

Click here to check market prediction for next trading session.

Get Daily Prediction & Stocks Tips On Your Mobile


I would like to receive communication from EquityPandit via sms, email, whatsapp, Google RCS for offers, updates etc.



πŸ“°
News
πŸ“ˆ
Prediction
πŸ“Š
FII / DII
πŸ‘”
Advisory
Get 1-2 Index Option Trades Daily